The BCL2 family: key mediators of the apoptotic response to targeted anticancer therapeutics

AN Hata, JA Engelman, AC Faber - Cancer discovery, 2015 - AACR
AN Hata, JA Engelman, AC Faber
Cancer discovery, 2015AACR
The ability of cancer cells to suppress apoptosis is critical for carcinogenesis. The BCL2
family proteins comprise the sentinel network that regulates the mitochondrial or intrinsic
apoptotic response. Recent advances in our understanding of apoptotic signaling pathways
have enabled methods to identify cancers that are “primed” to undergo apoptosis, and have
revealed potential biomarkers that may predict which cancers will undergo apoptosis in
response to specific therapies. Complementary efforts have focused on developing novel …
Abstract
The ability of cancer cells to suppress apoptosis is critical for carcinogenesis. The BCL2 family proteins comprise the sentinel network that regulates the mitochondrial or intrinsic apoptotic response. Recent advances in our understanding of apoptotic signaling pathways have enabled methods to identify cancers that are “primed” to undergo apoptosis, and have revealed potential biomarkers that may predict which cancers will undergo apoptosis in response to specific therapies. Complementary efforts have focused on developing novel drugs that directly target antiapoptotic BCL2 family proteins. In this review, we summarize the current knowledge of the role of BCL2 family members in cancer development and response to therapy, focusing on targeted therapeutics, recent progress in the development of apoptotic biomarkers, and therapeutic strategies designed to overcome deficiencies in apoptosis.
Significance: Apoptosis, long known to be important for response to conventional cytotoxic chemotherapy, has more recently been shown to be essential for the efficacy of targeted therapies. Approaches that increase the likelihood of a cancer to undergo apoptosis following therapy may help improve targeted treatment strategies. Cancer Discov; 5(5); 475–87. ©2015 AACR.
AACR